Heptabarbital

Summary

Heptabarbital (CHEMBL468837) is an approved small molecule (ATC N05CA11).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CA11
• Chemistry: 250.29 Da · C13H18N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL468837
Name	Heptabarbital
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10518
ATC	N05CA11
Molecular formula	C13H18N2O3
Molecular weight	250.29
InChIKey	PAZQYDJGLKSCSI-UHFFFAOYSA-N

SMILES: CCC1(C(=O)NC(=O)NC1=O)C2=CCCCCC2

IUPAC name: 5-(cyclohepten-1-yl)-5-ethyl-1,3-diazinane-2,4,6-trione

Also known as: Heptabarb, Heptabarbe, Heptabarbital, Heptabarbitone, Heptabarbo, HEPTABARBITAL, heptabarb

Patent coverage: 149 distinct patent families (593 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).